Bayer acquires Attralus’ cutting-edge cardiac amyloidosis imaging agents
The acquisition of AT-01 (124-Iodine-evuzamitide) and AT-05 (PAR-Peptide + technetium-99m) positions Bayer at the forefront of cardiac amyloidosis diagnostics
The acquisition of AT-01 (124-Iodine-evuzamitide) and AT-05 (PAR-Peptide + technetium-99m) positions Bayer at the forefront of cardiac amyloidosis diagnostics
The approval follows robust data from the SWIFT and ANCHOR Phase III trials
ADHD is a common, chronic neurodevelopmental disorder that often begins in childhood and can persist into adulthood
WCK 5222 is the first New Chemical Entity (NCE) discovered and developed in India to be submitted for pan-European marketing authorisation
Mepolizumab is the first and only monthly biologic in China tested for COPD patients with blood eosinophil counts (BEC) as low as 150 cells/µL
ICC is a highly aggressive liver cancer arising from the intrahepatic biliary epithelium
The drug had previously received orphan drug designation for this rare cancer on March 31, 2025
This production milestone positions Symbiosis at the forefront of meeting rising global demand for life-saving medicines
BBIL will guarantee production and supply of MTBVAC to more than 70 countries across Africa and Southeast Asia
Subscribe To Our Newsletter & Stay Updated